Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA

Lancet. http://ac.els-cdn.com/S014067361630592X/1-s2.0-S014067361630592X-main.pdf?_tid=2bbaab8c-6e22-11e6-91af-00000aacb361&acdnat=1472500552_267c801b1a8103d3afee87b33e288d1c   2016 Jul 26. pii: S0140-6736(16)30592-X. doi: 10.1016/S0140-6736(16)30592-X. [Epub ahead of print] Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Yaxley JW 1 ,  Coughlin GD 1 ,  Chambers SK 2 ,  Occhipinti S 3 ,  Samaratunga H 4 ,  Zajdlewicz L 5 ,  Dunglison N 1 ,  Carter R 6 ,  Williams S 7 ,  Payton DJ 8 ,  Perry-Keene J 8 ,  Lavin MF 9 ,  Gardiner RA 10 . Author information Abstract BACKGROUND: The absence of trial data comparing robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy is a crucial knowledge gap in uro-oncology. We aimed to compare these two approaches in terms of functional and oncological outcomes and report the early postoperative outcomes

·          in this single-arm, phase II study, the authors evaluated the efficacy and safety of nivolumab monotherapy in 80 adults with recurrent classical Hodgkin's lymphoma following failure of autologous stem-cell transplantation and brentuximab vedotin. After a median of 8.9 months of follow-up, 66.3% of patients achieved an IRRC-assessed objective response. Common adverse effects included fatigue (25%), reaction to the infusion (20%), and rash (16%). The most common grade ≥3 adverse events were neutropenia (5%) and increased lipase concentrations (5%). There were 3 deaths during the study period but none was thought to be related to therapy.            Treatment with nivolumab results in a response in the majority of patients with refractory                  Hodgkin's lymphoma, and the safety profile is acceptable. Nivolumab may represent a                   novel treatment option for this population. Hodgkin’s lymphoma is highly curable with chemotherapy

http://onlinelibrary.wiley.com/doi/10.1111/tbj.12662/epdf

http://mct.aacrjournals.org/content/early/2016/08/26/1535-7163.MCT-16-0196

http://ime.springerhealthcare.com/oncology/pilc2016/

http://ime.springerhealthcare.com/oncology/elcc2016/

http://ime.springerhealthcare.com/oncology/aplcc2016/

http://www.ejcancer.com/article/S0959-8049(16)32319-X/abstract http://www.ejcancer.com/article/S0959-8049(16)32319-X/pdf Abstract Purpose The 21-gene Recurrence Score assay (Oncotype DX) provides prognostic/predictive information in oestrogen receptor positive (ER+) early breast cancer, but access/reimbursement has been limited in most European countries in the absence of prospective outcome data. Recently, two large prospective studies and a real-life 5-year outcome study have been reported. We performed a pooled analysis of prospective European impact studies to generate robust data on impact of use in different clinical subgroups. Methods The analysis included four studies (French, German, Spanish, and British) in ER+ human epidermal growth factor receptor 2–negative breast cancer patients (n = 527). Node-positive patients were excluded. Results The analysis demonstrated that treatment recommendations changed in 32% of patients post-testing; chemotherapy recommendat

http://www.nejm.org/doi/full/10.1056/NEJMoa1602253 BACKGROUND The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical outcome in women with early-stage breast cancer. We sought to provide prospective evidence of the clinical utility of the addition of the 70-gene signature to standard clinical–pathological criteria in selecting patients for adjuvant chemotherapy. METHODS In this randomized, phase 3 study, we enrolled 6693 women with early-stage breast cancer and determined their genomic risk (using the 70-gene signature) and their clinical risk (using a modified version of Adjuvant! Online). Women at low clinical and genomic risk did not receive chemotherapy, whereas those at high clinical and genomic risk did receive such therapy. In patients with discordant risk results, either the genomic risk or the clinical risk was used to determine the use of chemotherapy. The primary goal was to assess whether, among patients with high-risk clinic

http://m.jco.ascopubs.org/content/early/2016/08/10/JCO.2016.68.3573.full http://m.jco.ascopubs.org/content/early/2016/08/10/JCO.2016.68.3573.full TUESDAY, Aug. 16, 2016 (HealthDay News) -- New surgery guidelines for treatment of women with ductal carcinoma in situ (DCIS) who undergo breast-conserving surgery with whole breast radiation could reduce both unnecessary surgeries and recurrence rates, three U.S. cancer groups say. The consensus guideline was published in the three groups' journals, the  Annals of Surgical Oncology ,  Practical Radiation Oncology , and the  Journal of Clinical Oncology . The guideline writing panel reviewed current evidence, including 30 studies with 7,883 patients. "The use of a 2-mm margin as the standard for an adequate margin in DCIS treated with whole breast radiation therapy is associated with low rates of recurrence of cancer in the breast and has the potential to decrease re-excision rates, improve cosmetic outcome, and decrease health

Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT  Jacob Farnebo, MDa,∗ , Agnes Wadelius, MDb , Per Sandström, MD, PhDb , Sten Nilsson, MD, PhDb , Hans Jacobsson, MD, PhDa , Lennart Blomqvist, MD, PhDa , Anders Ullén, MD, PhDb Abstract In this retrospective study, we evaluated the benefit of repeated carbon 11 (C11)-acetate positron emission tomography/computed tomography (PET/CT) to assess response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). A total of 30 patients with mCRPC were monitored with C11-acetate PET/CT and PSA levels during their treatment with AA. Retrospective evaluation of their response was made after 102 days (median; range 70–155) of treatment. Statistical analyses were employed to detect predictors of progression-free survival (PFS) and overall survival (OS), and potential corre

http://download.springer.com/static/pdf/191/art%253A10.1007%252Fs11060-015-2002-z.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs11060-015-2002-z&token2=exp=1471543487~acl=%2Fstatic%2Fpdf%2F191%2Fart%25253A10.1007%25252Fs11060-015-2002-z.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs11060-015-2002-z*~hmac=6646dda8db81fed70b182e4025316db7a552bf27bad72952118a16d572ced30c Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine D. H. Heiland1 • W. Masalha1 • P. Franco1 • M. R. Machein1 • A. Weyerbrock1 Received: 17 June 2015 / Accepted: 19 November 2015 / Published online: 27 November 2015 Springer Science+Business Media New York 2015 Abstract Bevacizumab (BEV) is widely used for treatment of patients with recurrent glioblastoma multiforme (GBM). 1-(2-Chlorethyl)-cyclohexyl-nitrosourea (CCNU, lomustine) monotherapy is an approved

http://theoncologist.alphamedpress.org/content/20/5/e13.full.pdf+html Is Dexamethasone a Better Partner for Abiraterone Than Prednisolone? I read with great interest the article by Auchus et al. [1] in which they comprehensively reviewed the use of prednisone with abiraterone acetate in the treatment of metastatic castrationresistant prostate cancer (CRPC). Although prednisolone is the most commonly used corticosteroid with abiraterone in clinical trials and is the standard of care as recommended by current guidelines, two recent trials have shown better response rates and progression-free survival with dexamethasone compared with prednisolone. In the first trial, Lorente et al. [2] showed that durable prostate-specific antigen (PSA) responses might be achieved with a switch from prednisolone to dexamethasone (0.5 mg/day) in patients progressing on abiraterone. In patients with CRPC and progressive diseasewith abiraterone-prednisolone, 11 of 30 patients (39%) had confirmed $30% PSA

Abstract BACKGROUND: Abiraterone  is a CYP17A1 inhibitor that improves survival in castration-resistant prostate cancer (CRPC).  Abiraterone  is licensed in combination with prednisone 5 mg twice daily to prevent a syndrome of secondary mineralocorticoid excess. We hypothesised that a 'steroid switch' from prednisone to  dexamethasone  would induce secondary responses in patients progressing on  abiraterone  and prednisone 5 mg b.i.d. METHODS: We performed a 'steroid switch' in patients with CRPC at PSA progression on  abiraterone  and prednisolone. Patients were monitored for secondary declines in PSA, radiological tumour regression and toxicity. RESULTS: A retrospective analysis of 30 CRPC patients who underwent a steroid switch from prednisolone to  dexamethasone  while on abiraterone  was performed. A total of six patients (20%) had a ⩾50% PSA decline that was confirmed by a second PSA level at least 3 weeks later. In all, 11 patients (39.2%) had a con

http://www.onclive.com/inside-oncology/oliver-sartor/monitoring-treatment-responses-with-radium-223-in-advanced-prostate-cancer

GLOBE NEWSWIRE via COMTEX) --- Improved clinical response seen for multiple symptoms associated with disease progression and overall survival, with notable lack of toxicity - Xilonix is the first antibody therapy to neutralize biological activity of interleukin-1 alpha (IL-1alpha), a potent anti-inflammatory signaling molecule known to promote the growth and spread of tumors - Xilonix granted accelerated review by the European Medicines Agency (EMA); an approval decision could come as early as fourth quarter 2016 AUSTIN, Texas, July 02, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human(TM) antibody therapies, today presented positive results from a pivotal Phase III trial of Xilonix(TM), the company's lead monoclonal (IgG1k) antibody immunotherapy for the treatment of advanced colorectal cancer (CRC). In the study, Xilonix-treated patients with advanced disease and multiple symptoms known to inversely correlate with overall surviva

Treatment with the combination of vemurafenib (Zelboraf) and cobimetinib (Cotellic) improved overall survival (OS) by 4.9 months compared with vemurafenib alone for patients with  BRAF  mutation-positive advanced melanoma, according to findings from the phase III coBRIM study presented at the 2015 Society for Melanoma Research (SMR) Congress. In the updated findings, the median OS was 22.3 months with the combination compared with 17.4 months with vemurafenib alone, representing a 30% reduction in the risk of death (HR, 0.70; 95% CI, 0.55-0.90;  P  = .005). The 1- and 2-year OS rates with the combination were 74.5% and 48.3%, respectively. “With about half of the people taking Cotellic and Zelboraf alive after two years, these data underscore the progress being made in cancer research toward better patient outcomes,” Sandra Horning, MD, chief medical officer and head of Global Product Development at Genentech, the company developing the combination, said in a statement. “Five years ago

http://www.onclive.com/publications/urologists-in-cancer-care/2016/August-2016/secondline-therapies-for-mcrpc-complicated-by-drug-interactions-and-dosing-issues Approximately four years after the FDA approval of two powerful new oral androgen-targeting agents for metastatic castrationresistant prostate cancer (mCRPC), an analysis raised issues complicating treatment with the two drugs, as well as what oncologists don’t yet know. The paper, published in Clinical Pharmacokinetics, 1  serves to heighten clinical awareness of the potential for both under-treatment and over-treatment with abiraterone acetate, as well as potential drug-drug interactions with both abiraterone acetate and enzalutamide. The study also takes a position on a discrepancy between the labeling approvals by the FDA and EMA. While regulatory agencies of both regions suggest that clinicians should avoid using enzalutamide along with strong CYP3A inducers such as oxycodone or methodone, the FDA suggests that an el

http://meetinglibrary.asco.org/content/81171?media=vm&poster=1

https://eorder.sheridan.com/3_0/app/orders/5765/